Trial record 7 of 104 for:    herbal medicine | Open Studies

Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Shanghai University of Traditional Chinese Medicine
Sponsor:
Collaborator:
Chongqing Three Gorges Central Hospital
Information provided by (Responsible Party):
Shanghai University of Traditional Chinese Medicine
ClinicalTrials.gov Identifier:
NCT01975454
First received: October 23, 2013
Last updated: October 28, 2013
Last verified: October 2013
  Purpose

Teng-Long-Bu-Zhong-Tang (TLBZT) is a modern anti-cancer herbal formula. Experimental studies have confirmed the anti-cancer potential of TLBZT against colorectal cancer. This trial will evaluate the safety and efficacy of TLBZT based herbal therapy in combination with chemotherapy in patients with metastatic colorectal cancer.


Condition Intervention Phase
Metastatic Colorectal Cancer
Drug: Chemotherapy
Drug: Herbal therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of Teng-Long-Bu-Zhong-Tang Based Herbal Therapy in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Shanghai University of Traditional Chinese Medicine:

Primary Outcome Measures:
  • Progression-free survival(PFS) [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • Symptoms [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 72
Study Start Date: April 2012
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: chemotherapy
Patients receive chemotherapy until disease progression or unacceptable toxicity
Drug: Chemotherapy
Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
Other Names:
  • Oxaliplatin
  • Capecitabine
Experimental: Herbal therapy plus chemotherapy
Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
Drug: Chemotherapy
Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
Other Names:
  • Oxaliplatin
  • Capecitabine
Drug: Herbal therapy
TLBZT based herbal decoction administered orally twice a day
Other Name: Traditional Chinese Medicine

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the colon or rectum with non-resectable metastatic disease;
  • Ages between 18 and 70 years;
  • Measurable lesion;
  • Karnofsky Performance Status ≥ 60%;
  • Estimated life expectancy of at least 6 months;
  • Participants have no major organ dysfunction and chemotherapy contraindications: hemoglobin ≥90g/L, N > 1.5×10^9/L, PLT≥ 100×10^9/L, normal liver and kidney function;
  • Informed consent from the patient.

Exclusion Criteria:

  • Symptomatic brain metastasis;
  • Adjuvant or neo-adjuvant treatment for non-metastatic disease in past 6 months;
  • Serious disease of heart, liver, kidney with severe dysfunction;
  • Serious complications, such as gastrointestinal tract obstruction and hemorrhage;
  • Pregnancy or breast-feeding women;
  • Mental or cognitive disorders;
  • Be participating other drug trials;
  • Who are allergic to the study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01975454

Contacts
Contact: Bing Hu, MD, PhD 86-21-64385700 beearhu@hotmail.com

Locations
China, Chongqing
Chongqing Three Gorges Central Hospital Recruiting
Chongqing, Chongqing, China, 404000
China, Shanghai
Longhua Hospital Recruiting
Shanghai, Shanghai, China, 200032
Sponsors and Collaborators
Shanghai University of Traditional Chinese Medicine
Chongqing Three Gorges Central Hospital
Investigators
Study Chair: Bing Hu, MD, PhD Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Principal Investigator: Gang Li, MD Chongqing Three Gorges Central Hospital
  More Information

Publications:
Responsible Party: Shanghai University of Traditional Chinese Medicine
ClinicalTrials.gov Identifier: NCT01975454     History of Changes
Other Study ID Numbers: TCM-mCRC, LHYY-11495801300
Study First Received: October 23, 2013
Last Updated: October 28, 2013
Health Authority: China: Science and Technology Commission of Shanghai Municipality

Keywords provided by Shanghai University of Traditional Chinese Medicine:
Metastatic colorectal cancer
Chemotherapy
Traditional Chinese Medicine (TCM)
Teng-Long-Bu-Zhong-Tang

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Oxaliplatin
Capecitabine
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2014